Actively Recruiting
Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA
Led by Institut Curie · Updated on 2026-05-06
300
Participants Needed
2
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.
CONDITIONS
Official Title
Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 18 or over
- Patient presenting an invasive tumor pathology (proven or suspected)
- Patient treated with immune-modulators or other treatments likely to modify immunological parameters
- Suspicion of immune mediated response or toxicities (assessed by immunologists)
- Peripheral venous capital usable and compatible with two venous accesses for lymphapheresis and absence of cardiovascular problems (heart failure, arrhythmia, etc.) as assessed by investigator
- Total circulating lymphocytes greater than 1000 / mm3
- Availability of DNA and RNA from the tumor
- Patient informed and signed informed consent or legal representative consent
- Affiliated with a social security scheme or equivalent
You will not qualify if you...
- Inability to undergo study follow-up for geographical, social, or psychological reasons
- Infection with HIV or hepatitis B or C viruses
- Patients on high dose corticosteroid treatment (> 1 mg / kg continuously)
- Any serious concomitant illness that may interfere with participation or significantly affect study results (pulmonary, heart, or liver disease)
- Contraindication to lymphapheresis (coagulation disorder, cardiovascular problems, venous access issues, hypocalcemia, psychological inability to undergo extracorporeal circulation, cachexia, etc.)
- Pregnant patient or of childbearing age without effective contraception
- Persons deprived of liberty, under guardianship, or legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Institut Curie
Paris, France, 75005
Actively Recruiting
2
Institut Curie
Saint-Cloud, France, 92210
Actively Recruiting
Research Team
C
Cyrine EZZILI, PhD
CONTACT
F
Fouzia AZZOUZ
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
FACTORIAL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here